logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8394385 B1

PDFFull Text
Date of Patent:
Mar. 12, 2013

Filed:

Mar. 09, 2010

Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against recombinant antigen in mva vaccines

Applicants:

Jürgen Hausmann, Gundelfingen, DE;

Karen Baur, Munich, DE;

Kay Brinkmann, Munich, DE;

Inventors:

Jürgen Hausmann, Gundelfingen, DE;

Karen Baur, Munich, DE;

Kay Brinkmann, Munich, DE;

Assignee:

Bavarian Nordic A/S, Kvistgaard, DK;

Attorney:

Law Office of Salvatore Arrigo and Scott Lee, LLP

Primary Examiner:

Louise Humphrey

Int. Cl.
CPC ...
A61K 39/275 (2006.01); A61K 39/285 (2006.01); A61K 39/12 (2006.01); A61K 48/00 (2006.01); A01N 63/00 (2006.01); A01N 65/00 (2009.01); C12Q 1/70 (2006.01); C12N 15/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

The invention is drawn to compositions and methods for the induction of a strong CD8 T cell response to a specific antigen(s). The combination of an early/late hybrid promoter directing strongly enhanced early expression of a neoantigen with at least three immunization rounds resulted in a highly efficient neoantigen-specific CD8 T cell response. This combination reversed the immunodominance hierarchy and converted a moderately immunogenic and subdominant CD8 T cell epitope into the immunodominant epitope.

Find Patent Forward Citations

Hausmann, Jürgen. (2013). Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against recombinant antigen in mva vaccines (U.S. Patent No. 8394385). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/8394385

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…